Specific immunotherapy effect on interleukin-18 and CD30 serum levels in monosensitized patients with rhinitis

Allergy and Asthma Proceedings

Volumn 24, Issue 3, 2003, Pages 179-183

  Ariano, Renato ^a   Merendino, Rosario A ^b   Minciullo, Paolo L ^b   Salpietro, Carmelo D ^b   Gangemi, Sabastiano ^b,c  

^a Sect of Allerg/Clinical Immunology   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CYTOKINE; ENZYME; INTERLEUKIN 18;

AGE; ALLERGIC RHINITIS; ALLERGY; ARTICLE; DONOR; GENDER; HUMAN; IMMUNOASSAY; IMMUNOREACTIVITY; IMMUNOTHERAPY; INFLAMMATION; SENSITIZATION;

ADOLESCENT; ADULT; ANTIGENS, CD30; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; INTERLEUKIN-18; MALE; MIDDLE AGED; RHINITIS;

EID: 0041418070     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bousquet J, Lockey RF, and Malling HJ. Allergen immunotherapy: therapeutical vaccines for allergic diseases. WHO Position Paper. Allergy 53(suppl 44):1-42, 1998.
2. Passalacqua G, Albano M, Fragonese L, et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in Mite-induced rhinoconjunctivitis. Lancet 351:629-632, 1998.
3. Purello D'Ambrosio F, Gangemi S, Isola S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhiniconjunctivitis, asthma, or both. Allergy 54:968-973, 1999.
4. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
5. Akdis CA, and Blaser K. Immunologic mechanism of specific immunotherapy. Allergy 54:31-32, 1999.
6. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of INF-gamma secretion in specific allergen-stimulated T cell cultures. J immunol 154:4187-4194, 1995.
7. Kashiwamura S, and Okamura H. IL-18 and IL-18 receptor. Nippon Rinsho 56:1798-1806, 1998.
8. Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor 12:53-72, 2001.
9. Del Prete GF, De Carli FM, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells with Th2 phenotype. FASEB 9:81-86, 1995.
10. Leonard C, Tormey V, Faul J, et al. Allergen-induced CD30 expression on T cells of atopic asthmatics. Clin Exp Allergy 27:780-786, 1997.
11. Durham SR, and Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 102:157-163, 1998.
12. Yashimoto T, Okamura H, Tagawa YI, et al. Interleukin 18 together with interleukin 12 inhibits IgE production by induction of interferon-γ production from activated B cells. Proc Natl Acad Sci USA 94:3948-3953, 1997.
13. Hofstra CL, Van AI, Hofman G, et al. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol 161:5054-5060, 1998.
14. Wild JS, Sigounas A, Sur N, et al. IFN-γ-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in mouse model of allergic asthma. J Immunol 164:2701-2710, 2000.
15. Tanaka H, Miyazaki N, Oashi K, et al. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 107:331-336, 2001.
16. Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increase the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 97:1356-1365, 1996.
17. Hamid Q, Schotman E, Jacobson M, et al. Increases in interleukin-12 (IL-12) messenger RNA+ (mRNA+) cells accompany inhibition of allergen induced late skin responses following successful grass pollen immunotherapy. J Allergy Clin Immunol 99:254-260, 1997.
18. Park HS, Nahm DH, Kim HY, et al. Clinical and immunologic changes after allergen immunotherapy with Hop Japanese pollen. Ann Allergy Asthma Immunol 86:444-448, 2001.
19. Purello D'Ambrosio F, Gangemi S, Merendino RA, et al. Prevention of new sensitization in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 31:1295-1302, 2001.